Arcus Biosciences (RCUS) Enterprise Value (2017 - 2026)

Arcus Biosciences' Enterprise Value history runs 10 years deep, the most recent figure standing at -$822.0 million for Q1 2026.

• On a quarterly basis, Enterprise Value rose 17.55% year-over-year to -$822.0 million in Q1 2026; TTM through Mar 2026 was -$822.0 million, a 17.55% increase from a year earlier, with the FY2025 full-year figure at -$981.0 million, changed 0.31% from the prior year.
• Enterprise Value grew to -$822.0 million in Q1 2026 per RCUS's latest filing, from -$981.0 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$759.0 million in Q4 2023 and bottomed at -$1.2 billion in Q1 2022.
• The 5-year median for Enterprise Value is -$978.0 million (2024), against an average of -$968.2 million.
• Across the five-year window, Enterprise Value slumped 102.2% in 2022 and increased 24.78% in 2023, its largest moves.
• Year by year, Enterprise Value stood at -$1.0 billion in 2022, then rose by 24.78% to -$759.0 million in 2023, then declined by 28.85% to -$978.0 million in 2024, then dropped by 0.31% to -$981.0 million in 2025, then gained by 16.21% to -$822.0 million in 2026.
• Per Business Quant, the three latest RCUS Enterprise Value figures stand at -$822.0 million (Q1 2026), -$981.0 million (Q4 2025), and -$831.0 million (Q3 2025).